Skip to main content
Journal ArticleOPEN ACCESS

LCZ696 (sacubitril/valsartan) for patients with heart failure

Cochrane Database of Systematic Reviews (2020) 2020(1)
DOI: 10.1002/14651858.CD013517
0Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.

Cite

CITATION STYLE

APA

Hernandez, A. V., Pasupuleti, V., Banach, M., & Bielecka-Dabrowa, A. M. (2020). LCZ696 (sacubitril/valsartan) for patients with heart failure. Cochrane Database of Systematic Reviews, 2020(1). https://doi.org/10.1002/14651858.CD013517

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free